No Notable Legislation

Task force established in 2024 to prepare for the regulation of psychedelics in case of FDA approval delivered its final report in February 2026. In 2025, activists submitted the Alaska Natural Medicine Act, a ballot initiative, for consideration on the 2026 ballot, but it failed to collect the requisite signatures by the end of 2025. The group is now targeting the 2028 ballot.

2026

In February, the Alaska Legislative Task Force for the Regulation of Psychedelic Medicines released its final report on February 4, 2026, which included 25 policy recommendations. The first, broadest recommendation states: “If and when psychedelic medicine therapies are FDA approved, the state should take action to allow for their use in Alaska, rather than prohibiting use.”

2025

Activists filed the Alaska Natural Medicine Act, an initiative they hope to get on the ballot in 2026. It would decriminalize and regulate the use, possession, and cultivation of psychedelics including psilocybin, psilocyn, dimethyltryptamine, and mescaline. In December, the campaign announced that it had not collected the requisite signatures to appear on the 2026 ballot and that it will now focus on the 2028 ballot.

2024

HB 228, “an act establishing the Alaska task force for the regulation of psychedelic medicines approved by the United States Food and Drug Administration,” became law in 2024. The task force, which is composed of various stakeholders including government officials, healthcare professionals, and community representatives, will prepare for the potential medicalization of psychedelic substances in the state. More specifically, the task force will be charged with making policy recommendations on issues related to insurance, licensure, implementation, and other necessary regulatory changes.

$5 million has been earmarked in Arizona’s FY2026 budget to fund studies of ibogaine. In 2026, multiple psychedelics-related bills were introduced.

2026

SB 1542 was introduced in January. If enacted, it would appropriate $10 million for trials, research and training about MDMA as treatment for PTSD for first responders and veterans. It would expand workers’ compensation for firefighters and peace officers who have PTSD to “potentially include” MDMA treatment.

SB 1752 was introduced in February. If enacted, it would prohibit harvesting, processing or commercial use of mescaline, but protect religious use. It was introduced in February.

2025

Introduced by Representative Justin Wilmeth (R), HB 2871 proposed $5 million in match-funding from the state general fund for a clinical study on ibogaine’s potential to treat neurological diseases, including traumatic brain injury and PTSD. As of summer 2025, the bill had passed the House but was held in Senate after its second reading. Despite failing to pass through the remainder of legislative process, the financial appropriation did make its way into Arizona’s general budget for FY2026.

Representative T. J. Shope (R) introduced SB 1555, originally modeled after Oregon's regulated psilocybin services, though the House Health and Human Services Committee replaced that text with a crystalline polymorph psilocybin trigger law before enactment. This bill follows SB 1570, a similar 2024 legislative effort that was vetoed by Governor Hobbs. However, the House’s Health and Human Services Committee replaced the text of the new 2025 bill with a rescheduling trigger law bill. 

SB 1555 was signed into law by Governor Hobbs on approximately April 22, 2025. As enacted, the bill is a crystalline polymorph psilocybin rescheduling trigger law (conditional on FDA approval and DEA rescheduling by January 1, 2031), not the Oregon-style services model of the introduced version.

2024

In a 2024 decision, Governor Katie Hobbs vetoed SB 1570. If passed, the bill would have created a regulatory framework to govern facilitated therapeutic access to on-site psilocybin services. Despite passing through the Senate and House with significant support, the bill was vetoed over concerns about premature clinical expansion and financial implications.

2023

In 2023, HB 2486 was proposed to appropriate $30 million from the state budget for psilocybin research grants and establish a psilocybin research advisory council. The bill died in committee.

No Notable Legislation

Resolutions unanimously passed in the cities of Oakland, Santa Cruz, Arcata, Berkeley, and San Francisco have made personal use and possession of certain psychedelics the lowest law enforcement priority.

2025

AB 2489, introduced in February, would allow the state’s Research Advisory Panel to submit FDA applications for clinical trials using some Schedule I and II controlled substances, including psilocybin, for veterans.

Introduced by Chris Ward (D), AB 1103 would enable some psychedelic-focused research studies to benefit from expedited reviews and approval timelines by effectively bypassing the full RAP-C review process. Qualifying applications would be assigned to a smaller cohort of Research Advisory Panel members who would be authorized to approve those applications without the need for a full panel vote. The bill was signed into law on October 10, 2025.

Introduced by Josh Becker (D) and co-sponsored by nine bipartisan lawmakers, SB 751 would establish a Veterans and First Responders Research Pilot Program to focus on the research and development of psilocybin services in up to five counties. It could be reconsidered in 2026.

2023

Introduced by Assembly Member Marie Waldron in February 2023, AB 941 would have required California’s Health and Human Services Agency to contravene a working group to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy. The original bill also included provisions to authorize the administration of psychedelic assisted therapies to treat combat veterans suffering from traumatic brain injuries, post-traumatic stress disorder, or addiction. AB 941 eventually died in the Senate.

State Senator Scott Wiener introduced SB 58, a bill that would have legalized the possession, transportation, transfer, preparation, and obtaining of allowable amounts of psilocybin, psilocin, dimethyltryptamine (DMT), ibogaine, and mescaline (excluding peyote) for personal use or facilitated/supported use by individuals 21 years of age or older. After passing the Senate in September 2023, Governor Gavin Newsom vetoed SB 58 on October 7, 2023.  

2021

Senator Scott Wiener introduced SB 519, which would have removed criminal penalties for personal use possession and social sharing of psilocybin, psilocin, MDMA, LSD, DMT, ibogaine, and mescaline (excluding peyote). Ketamine was initially included in the list of compounds, but was removed in the Assembly by committee amendment. The original bill also included provisions to dismiss and seal prior drug convictions that would no longer be unlawful; that language was removed in the Senate. Despite being approved by the Senate, SB519 stalled in the Assembly Appropriations Committee, and officially died on November 2022. 

In a historic 2022 vote, Coloradans passed Proposition 122, becoming the second U.S. state to legalize and regulate psychedelics and the treatment centers for their use. At the local level, in 2019, with the passage of Initiative 301 Denver became the first U.S. city to deprioritize law enforcement for possession of psilocybin mushrooms. 

2025

SB 25-297, introduced by Matt Ball (D) and Lisa Feret (D), would require Colorado’s Department of Public Health and Environment to collect de-identified data on natural medicine use from healing centers and licensed facilitators, including client demographics and health outcomes. On June 3, 2025, SB 25-297 was signed into law.

2023

In April 2023, Senate President Steve Fenberg (D) introduced SB 23-290 in order to establish the regulatory framework needed to support the state’s Natural Medicine Program. The bill was signed into law by Colorado Governor Polis on May 23, 2023.

2022

In early 2022, activists filed Initiative 58 and Initiative 59, which are revised versions of the “Natural Medicine Health Act of 2022” previously proposed in Initiatives 49 and 50 (see 2021 efforts below). On July 21, 2022, it was announced that Initiative 58 received enough signatures to qualify for the 2022 general election ballot. The initiative subsequently appeared as Proposition 122, the Decriminalization and Regulated Access Program for Certain Psychedelic Plants and Fungi Initiative. 

While initiative 59 expired, in November 2022, the voters of Colorado passed Proposition 122, making Colorado the second state in the country to enact a regulated access program for psychedelics. Proposition 122 subsequently led to the establishment of the Natural Medicine Advisory Board which advised Colorado regulators on the creation of state sanctioned “healing centers.”

Connecticut has enacted psychedelic policy reform: in 2021, the governor signed SB 1083, directing the Department of Mental Health to study the health benefits of psilocybin; in 2022, the governor signed HB 5506, which earmarked state budget funds for a psilocybin and MDMA-assisted therapy pilot for veterans, retired first responders, and health care workers at FDA-approved treatment sites. A bill to expand access to the state’s psychedelic-assisted therapy pilot program is being considered in 2026.

2026

SB 00191 would expand access to the state’s psychedelic-assisted therapy pilot program. It was introduced in February.

2025

Filed jointly by State Rep. John Sweeney (D) and Rep. MJ Shannon (D), HB 5456 was crafted in coordination with prominent advocacy group Connecticut for Accessible Psychedelic Medicine (CAPM) and per CAPM co-founder Victor Constantza is modeled after New York’s SB 495, and similarly, CT HB 5456’s proposed program would allow trained and state-approved facilitators, such as healthcare and social work professionals, to offer psilocybin-assisted therapy to qualified patients.

Separately to CAPM’s legislative outreach efforts, longtime CT state drug policy reform supporter Rep. Josh Elliott (D) filed HB 6380 that as of January 23 was referred to the State’s judiciary committee for consideration and further review.

As for Connecticut’s State Senate, a noteworthy appropriations bill, SB 855, was filed by Sen. Martha Marx (D) and quickly referred to the state’s Joint Appropriations Committee for further review. As proposed, SB 855 would direct a to-be-determined amount of funding to the Department of Mental Health and Addiction Services, “for the Fiscal year ending June 30, 2026, for the administration of a psychedelic-assisted therapy program.”

Introduced by the House Judiciary Committee, HB 7065 would decriminalize possession of less than half an ounce of psilocybin.

2023

Rep. David Michel (D) and Sen. Gary Winfield (D) introduced HB 5102, which would “allow the use of psilocybin for medicinal and therapeutic purposes, including, but not limited to, the provision of physical, mental or behavioral health care.” The proposed bill merely provides that “the general statutes be amended to allow” such use. It was referred to the Joint Committee on Public Health.

HB 6146 was referred to the Joint Committee on Public Health after being introduced by Rep. Michelle L. Cook (D). This bill would implement a psychedelic assisted therapy pilot program by appropriating money from the General Fund. On February 8, 2023, the bill was referred to the Appropriations Committee.

Connecticut HB 6734, “An Act Concerning the Decriminalization of Possession of Small Amounts of Psilocybin,” introduced by the Judiciary Committee, was passed by the House on May 10, 2023. HB6734 would eliminate criminal penalty for possessing less than ½ ounce of psilocybin and for possessing paraphernalia related to less than ½ ounce of psilocybin; requires temporary loss of driver’s license for possessing greater than ½ ounce of psilocybin, when under 21-years of age. Proposed Effective Date: October 1, 2023.

2022

The governor signed HB 5506 adjusting the state budget for the biennium, effective from July 1, 2022 to June 30, 2023. This state budget bill specifically earmarked funds for psychedelic-assisted therapy programs administering psilocybin and MDMA treatments. Under the pilot program, veterans, retired first responders, and direct care health care workers can be qualified to receive MDMA-assisted or psilocybin-assisted therapy under the supervision of an approved federal Food and Drug Administration treatment site.

2021

The governor signed into law SB 1083 that calls upon the Department of Mental Health and Addiction Services to convene a working group “to study the health benefits of psilocybin” and examine “whether the use of psilocybin by a person under the direction of a healthcare provider may be beneficial to the person’s physical or mental well-being.” The working group was directed to “submit a report on its findings and recommendations” no later than January 1, 2022.

No Notable Legislation

Legislators considered psychedelics-related bills in previous sessions, but none are currently under review.

2025

Florida’s Farm Bill, SB 700, includes a provision that makes it a misdemeanor to “transport or offer to transport, import into this state, sell or offer for sale, furnish, or give away spores or mycelium capable of producing mushrooms or other material which will contain a controlled substance, including psilocybin or psilocyn, during its lifecycle.” The bill was signed by Governor Ron DeSantis on May 15, 2025, and took effect July 1, 2025. Violation is a first-degree misdemeanor, punishable by up to one year in jail and a $1,000 fine.

2022

Senate Minority Leader Lauren Book (D) and Representative Michael Grieco (D), the Ranking Minority Leader of the House Subcommittee on Criminal Justice and Public Safety, have also introduced bills that would require officials in the state to “conduct a study to evaluate the therapeutic efficacy of alternative therapies,” including MDMA, psilocybin, and ketamine, to treat conditions such as depression, anxiety, PTSD, bipolar disorder, chronic pain, and migraines. The bills, introduced as SB 348 and HB 193 (“Using Alternative Therapies to Treat Mental Health and Other Medical Conditions”), were modelled on the legislation enacted into law in Texas on June 18, 2021 (HB 1802). Both bills died in committee in March 2022. 

2021

Representative Dotie Joseph (D) introduced HB 725, the “Collateral Consequences of Convictions and Decriminalization of Cannabis and All Drugs Act.”  The bill states “Crimes associated with the personal usage and possession of controlled substances that do not involve production, distribution or sale shall be decriminalized in favor or [sic] civil fines and referral for drug rehabilitation.” In March 2022, the bill died in the Criminal Justice & Public Safety Committee.

A different bill introduced in the previous legislative session (“The Florida Psilocybin Mental Health Care Act,” HB 549), aimed to legalize and regulate the use of psilocybin for mental health treatment.  That bill died on April 30, 2021 in the Professions & Public Health Subcommittee.

State lawmakers have proposed the creation of a three-year pilot program focused on ‘breakthrough treatments’, including ibogaine, for veterans and retired first responders. They have also proposed allowing psychedelic-assisted treatment and therapy to be provided by certain licensed healthcare professionals, once FDA approved. 

2026

HB 1296, introduced in February, would create a three-year pilot program focused on “breakthrough treatments: for veterans and retired first responders suffering from conditions including PTSD, treatment-resistant depression and traumatic brain injury. The bill mentions ibogaine.

2025

Introduced by Representatives Ron Stephens (R) and Mark Newton (R), HB 382 is another Compass Pathways-backed rescheduling trigger law bill of the “crystalline polymorph psilocybin” variety. According to the bill’s current form, if a drug containing crystalline polymorph psilocybin is approved by FDA, it shall be scheduled in Georgia in accordance with its federal schedule.

Introduced by a bipartisan suite of state Representatives, HB 717 would amend Georgia law to allow psychedelic-assisted treatment and therapy to be provided by certain licensed healthcare professionals, once FDA approved. 

Neither HB 717 nor HB 382 were passed during the 2025 legislative session, but both could be reconsidered in the 2026 session.

2022

A group of bipartisan Georgia legislators proposed HR 896, which would create the House Study Committee on Alternative Post-Traumatic Stress Disorder Treatment Resources for Veterans. If formed, the five-member committee would “undertake a study of the conditions, needs, issues, and problems” related to utilizing psilocybin-assisted therapy to treat veterans suffering from PTSD or depression and for other purposes, such as to treat people struggling with addiction. The committee would also be empowered to “recommend any action or legislation which the committee deems necessary or appropriate.” The bill died in committee.

State legislators have introduced psychedelics-related bills in 2026.

2026 

SB 3199 was introduced in January. If enacted, it would create a task force to run a two-year project to prepare the state to integrate therapy using psychedelic compounds that are in FDA-regulated trials, have FDA approval, or have been authorized for medical use in Hawai’i, including MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for depression. It was introduced in January.

SB 1042 was introduced in 2025 and carried over to the 2026 legislative session. If enacted, it would create a two-year psychedelics pilot program, focusing on veterans experiencing PTSD. 

SB 967 was introduced in 2025 and carried over to the 2026 legislative session. If enacted, it would require insurers (including Medicaid) to provide coverage of IV ketamine for treatment-resistant depression.

2025

Introduced by Senator Stanley Chang (D), SB 1042 would establish a 2 year Mental Health Emerging Therapies Pilot Program aimed at generating a public-private partnership to fund Phase 3 trials of candidates that hold FDA Breakthrough Therapy Designations, including psychedelics. SB 1042 passed the House, with substantial amendments with which the Senate disagreed.

2023

HB 1340 (along with companion bill SB 1531) was introduced to the House by 13 primary sponsors. The Health and Human Services Committee recommended the measure be passed on March 22, 2023, followed by a similar recommendation in the Ways and Means Committee on April 4, 2023 by a unanimous vote. The bill would “establish a Temporary Breakthrough Therapy Designation Advisory Council within 3 months of certain breakthrough therapy designation approvals by the United States Food and Drug Administration.” On March 10, 2023 Senator Chris Lee (D) introduced a bill, SCR 69 titled “Requesting The Department Of Health To Establish A Beneficial Treatments Advisory Council To Review, Evaluate, And Recommend New Medicinal Mental Health Treatments.” The bill would “plan to ensure the safe, accessible, and affordable availability of therapeutic psilocybin, psilocybin—based products, and MDMA for adults ages twenty—one years old.” A public hearing was scheduled on March 24, 2023 and the Health and Human Services Committee deferred the measure that day.

2022

Senate Bill 2575 was introduced proposing to remove “psilocybin and psilocin from the list of Schedule I substances” and “establish designated treatment centers for the therapeutic administration of psilocybin and psilocin.” If enacted, this bill would also require the governor to “establish and convene a psilocybin review panel to review and assess the effects of this Act.” The panel would be mandated to provide a report, including any proposed legislation, to the legislature each year until 2027, at which point the panel would be disbanded. On January 24th, 2022, the bill passed its first reading, and was referred to the HTH and JDC/WAM committees.  

Senate Bill 3160 was proposed to have the Hawaii Department of Health create a “therapeutic psilocybin working group to examine the medicinal and therapeutic effects of psilocybin and develop a long-term strategic plan to ensure the availability of therapeutic psilocybin or psilocybin-based products that are safe, accessible, and affordable for adults twenty-one years of age or older.” If formed, the therapeutic working group would be tasked with examining: laws and regulations related to the therapeutic use of psilocybin; available medical research pertaining to the safety and efficacy of psilocybin in treating mental health conditions; and the requirements, specifications, and guidelines for a medical professional to prescribe and provide psilocybin to patients in jurisdictions in which psilocybin is used to treat mental health conditions.” On March 8, 2022, SB3160 was unanimously approved by the Hawaii State Senate and has advanced to the State House for further consideration.

The Hawaii Senate approved two identical resolutions sponsored by Senator Chris Lee (D), SCR100 and SR88, which requested that the Hawaii Department of Health “convene a therapeutic psilocybin working group.” However, prior to approval, the Hawaii Senate amended the resolutions making access to psilocybin and psilocin dependent on FDA approval.

2021

Senate Bill 738 was introduced, which would remove psilocybin and psilocin from the list of Schedule I substances and require the Department of Health to establish designated treatment centers for their therapeutic administration. On February 23, 2021 it was deferred by the Judiciary Committee.

House Concurrent Resolution No. 174 was introduced, which calls for a “Therapeutic Psilocybin Working Group” to be established in the Health Department and for members to study the current laws governing psilocybin, the existing research related to the “safety and efficacy” of psychedelics for mental health treatment, and propose guidelines for medical professionals to “prescribe and provide psilocybin” to patients. The working group “is requested to develop a long-term strategic plan to ensure the availability of therapeutic psilocybin or psilocybin-based products that are safe, accessible, and affordable for adults twenty-one years of age or older.” 

A parallel resolution (S.C.R. No. 208) was introduced in the Senate on March 12, and adopted after amendment on March 31. It was sent back to the house on April 1, 2021.

No Notable Legislation

State legislators have proposed the formation of a psilocybin advisory board.

2026

SB2772 would establish a state psilocybin advisory board within the Department of FInancial and Professional Regulation. It was introduced in January.

2025

For the third year running, Illinois State Rep. LaShawn Ford (D) filed HB 1143, formally titled The Compassionate Use and Research of Entheogens Act, which would establish the Illinois Psilocybin Advisory Board in coordination with the state’s Department of Public Health, Department of Agriculture, Department of Financial and Professional Regulation, the Department of Revenue, and the Illinois State Police.

Introduced by Representative Theresa Mah (D), HB 2992 would develop a pilot program to create more access to regulated psilocybin-assisted therapy. It would also develop an advisory board for the program; the board would be able to consider and recommend expanding the program to include other psychedelics.

2023

Reps. La Shawn Ford (D) introduced HB0001, the Illinois CURE (Compassionate Use and Research of Entheogens) Act. The Act would establish the Illinois Psilocybin Advisory Board within the Department of Public Health for the purpose of advising and making recommendations to the Department regarding the provision of psilocybin and psilocybin services. The Department would begin receiving applications for the licensing of persons to manufacture or test psilocybin products, operate service centers, or facilitate psilocybin services. The Act also provides for the expungement of records concerning the possession of psilocybin and psilocin, and amends the Illinois Controlled Substances Act to remove psilocybin and psilocin from the list of Schedule I controlled substances. It was re-referred to the Rules Committee on April 5, 2024.

Sen. Rachel Ventura introduced legislation to amend the Illinois Controlled Substances Act. SB 2353 “[p]rovides that notwithstanding any other provision of the Act to the contrary, including the scheduling of psilocybin as a Schedule I controlled substance, the Department of Financial and Professional Regulation shall authorize the distribution of, and make publicly available, psilocybin for medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin and other entheogens to treat mental health conditions, including, but not limited to, addiction, depression, anxiety disorders, headache disorders, and end-of-life psychological distress. Provides that the Department of Financial and Professional Regulation shall begin receiving applications for the registration of persons to perform the following: (1) manufacturing psilocybin products; (2) operating a service center; (3) facilitating psilocybin services; and (4) testing psilocybin products.”

2022

Evanston, Illinois council member Devon Reid announced intentions to sponsor legislation in December 2022, which would decriminalize the “planting, cultivation, delivery, possession with intent to deliver, or possession of entheogenic plants and the derivative controlled substances,” making the penalty for any of the aforementioned conduct punishable by a civil fine not to exceed $100. However, the fine may be waived if the violator completes an approved rehabilitation program or performs some form of reasonable public service work. The proposed legislation notes that entheogenic plants include, but are not limited to, psilocybin, psilocin, Lophophora williamsii, and Banisteriopsis caapi. This bill would also make the investigation or arrest of planting, cultivating, purchasing, transporting, distributing, or engaging in practices with or possessing entheogenic plants the lowest law enforcement priority.

2020

Chicago’s Committee on Health and Human Relations heard R2019-735 an “Expression of support for adult use of Entheogenic Plants and call for hearing(s) to discuss findings from Department of Public Health on feasibility of use of Entheogenic Plants and its plant compounds as alternative treatment options.” The resolution was heard but not passed.

In March 2024, Indiana enacted a therapeutic psilocybin research fund (as part of House Bill 1259, signed by Governor Holcomb on March 13, 2024). In 2025, HB 1166 appropriated up to $600,000 to fund this program. In 2026, SB 0173 would allow some practitioners to provide “neuroplastogen treatment,” including psilocybin, to qualifying patients with life-threatening conditions.

2026

SB 0173 would allow some practitioners to provide “neuroplastogen treatment,” including psilocybin, to qualifying patients who have life-threatening conditions; allows for research on “neuroplastogen access.” It was introduced in January.

2025

Justin Moed (R), Jake Teshka (R), and Garrett Bascom (R) filed HB 1166, an appropriations bill that would allocate up to $600,000 over 2025 and 2026 to fund an existing psilocybin research program that was signed into law last March by then Governor Eric Holcomb (R).

2024

SB 139, introduced on January 8, 2024, would establish the "therapeutic psilocybin research fund" administered by the Indiana Department of Health. The fund aims to offer financial assistance to research institutions in the state studying the use of psilocybin for treating mental health and other medical conditions. The bill also outlines clinical study requirements. Institutions conducting psilocybin studies are obligated to submit a report to the “interim study committee on public health, behavioral health and human services, state department, and division of mental health and addiction.” On February 13, 2024, the bill was referred to the Ways and Means Committee.

Legislators considered psychedelics-related bills in previous sessions, but none are currently under review.

2026

HF 2085 would create a state psilocybin system. It was introduced in January.

SF 2151 would remove psilocybin and psilocin from Schedule I in the state. It was introduced in January. (The House version of the bill, introduced in February 2025, is IA HF 351.)

2025

Filed by Ann Meyer (R), Iowa HF 14 is a psilocybin-focused trigger bill. In March 2025, it was replaced by SSB 1177, which would reschedule FDA-approved and federally rescheduled psilocybin.

HF 383, a crystalline polymorph psilocybin trigger bill, passed both chambers unanimously but was vetoed by Governor Reynolds on June 11, 2025 (formerly HF 14). HF 383 passed the House 92–0 and the Senate 47–0.

Introduced by Representatives Jeff Shipley (R), Josh Turek (D), and Ray Sorensen (R), HF 351 would remove psilocybin and psilocyn from Schedule I in the state. Shipley has introduced related bills in the past, including HF 248 and HF 249 in 2019. In 2025, Shipley also introduced HF 609, which would amend state law to clarify that the use of psychedelics in religious or spiritual ceremonies was protected as exercise of religion.

John Wills (R) introduced HF 620, which would establish a system for legally producing psilocybin and administering it to people with PTSD. In March 2025, HF 620 was replaced by HF 978, which would create a state legal system for using psilocybin to treat PTSD.

2023

HF240 was introduced to the House on February 8, 2023 and would remove “psilocybin and psilocin” from the list of Schedule I controlled substances in the state. Passage was recommended by the subcommittee on April 11, 2023.

2021

HF480 was introduced February 11, 2021 and referred to Human Resources. The bill proposes decriminalizing certain schedule I controlled substances, including DMT, LSD, peyote, psilocybin, psilocin, and MDMA, for use by certain patients diagnosed with a terminal illness or a life-threatening disease or condition.

HF636 was introduced February 23, 2021 and referred to the House Public Safety Committee. The bill proposes creating a Psilocybin Services Act to, in part, provide for regulated administration of psilocybin products to individuals 21 years of age and older in the state. The bill would deprioritize criminal prosecution of noncommercial activities related to entheogenic plants and compounds including ibogaine, DMT, mescaline, peyote, psilocybin, and psilocin.

HF459 aimed to remove psilocybin and psilocin from Schedule 1 controlled substances, but was indefinitely postponed on March 3, 2021.

A rescheduling trigger law bill was recommended for passage by committee in January 2026 but has not been enacted.

2026 

In January, the Committee on Health and Human Services recommended HB 2218 be passed as amended.

2025

HB 2218, introduced by the Committee on Health and Human Services, is a rescheduling trigger law bill that moves “the pharmaceutical composition of crystalline polymorph psilocybin, known as COMP 360 or any such trade name approved by the United States food and drug administration” from Schedule I to Schedule IV. In January 2026 the Committee on Health and Human Services recommended the bill be passed as amended.

2022

On January 10, 2022, Kansas lawmaker Rep. Aaron Coleman (D) introduced HB 2465, or  the “Legalized Homegrown Psilocybin Mushroom Act of 2022,” aimed at reducing the penalty for individuals cultivating or possessing small quantities of psilocybin or psilocin. This bill came following a failed effort to pass similar legislation, HB 2288, introduced by the same legislator in February 2021. HB 2465 died in committee on May 23, 2022.

The legislature is considering funding research into ibogaine as a treatment for opioid dependence.

SB 77 was introduced in January. If enacted, it would create the Ibogaine Research and Intellectual Property Fund, appropriating $21 million from the opioid abatement trust fund over two fiscal years (2026-2028) to fund a public-private partnership with a drug developer for clinical trials.

2025

Introduced by Don Douglas (R), Lindsey Tichenor (R), and Shelley Frommeyer (R), SB 240 would promote research into ibogaine as a potential therapy for opioid dependence and co-occurring mental health disorders. It would also establish The Ibogaine Research Fund so that private entities in Kentucky could contribute to the costs of ibogaine research. 

2023

On January 4, 2023, HB 98 was introduced, titled “An Act Relating to Controlled Substances.” If passed, the bill would “amend possession of controlled substance statutes to reduce penalty.” It would also amend state law “to provide for referrals to treatment for persons charged with possession of controlled substances,” and “to decriminalize possession of items to test, store, or consume controlled substances.” In addition, the bill would establish a program for harm reduction centers.

On May 31, 2023, the Kentucky Opioid Abatement Advisory Commission (KYOAAC), chaired by Bryan Hubbard, announced at a press conference hosted by Attorney General Daniel Cameron that it was exploring the possibility of allocating no less than $42 million from the state's opioid settlement funds to ibogaine research over six years. The proposal remained subject to a commission vote that was never taken. Following incumbent Governor Beshear's re-election and the subsequent change in the Attorney General's office, incoming AG Russell Coleman replaced Hubbard as commission chair. At the KYOAAC's first meeting under Coleman's leadership on January 4, 2024, the proposal was formally rejected. No funds were ever allocated or disbursed.

In February, a bill to create a state psychedelic-assisted therapy research program was introduced.

2026

SB43 would create a psychedelic-assisted therapy research program in the state Department of Health. It was introduced in February.

Legislators considered psychedelics-related bills in previous sessions, but none are currently under review.

2025

LD 1034, introduced by Representative Grayson Lookner (D) and co-sponsored by a bipartisan set of lawmakers, would amend state law to effectively decriminalize the personal possession of one ounce or less of psilocybin among adults. This bill won’t  be deliberated upon in the current legislative session.

2024

LD1914 would enact the Maine Psilocybin Health Access Act. Following a model similar to Oregon, this act would allow for the administration of psilocybin from licensed manufacturers, at licensed service centers under the supervision of licensed psilocybin facilitators. Additionally, this act would also decriminalize the personal possession, growing, and use of small amounts of psilocybin by persons 21 and older. It passed the House in April, 2024; in May 10, 2024, the Senate carried the bill over to special session.

2022

SP 496 (LD 1582), originally introduced in 2021 by Sen. Donna Bailey (D), would have enacted the Maine Psilocybin Services Act, and legalized the facilitated use of psilocybin at licensed service centers, similar to Oregon’s Psilocybin Services. The Maine Senate voted to pass SP496. However, shortly thereafter, the Maine House of Representatives declined to advance the proposal. Following the proposal’s stall in the Maine House, Senator Bailey indicated in an interview with Marijuana Moment that she intends to reintroduce the proposal in the next legislative session or potentially pursue a peoples’ referendum.

2021

HP 713 (LD 967) would have made possession of scheduled drugs for personal use merely a civil penalty. That legislation was rejected by the Senate 14-18 on June 30, 2021, after being approved by a 77-62 vote in the House.

In 2025, Maryland’s Task Force on Responsible Use of Natural Psychedelic Substances released a report recommending a “multi-pathway framework for safe, broad, and equitable access to natural psychedelic substances, with an initial focus on psilocybin.” In 2022, a fund was established to research treatments for PTSD that include psychedelics. 

2026

HB 427 would extend the Task Force on Responsible Use of Natural Psychedelic Substances through December 31, 2027. It was introduced in January.

HB 1477/SB 527, which was introduced in February, would establish grants so that research institutions in Maryland could conduct certified clinical drug development trials about ibogaine as a treatment for opioid use disorder and other neurological conditions.

2025

In November, the Task Force on Responsible Use of Natural Psychedelic Substances released its report to the state’s General Assembly (PDF). It recommended that the state adopt a “multi-pathway framework for safe, broad, and equitable access to natural psychedelic substances, with an initial focus on psilocybin.”

2024

In a 2024 decision, the Governor of Maryland approved House Bill 548, Task Force on Responsible Use of Natural Psychedelic Substances. This bill establishes the Task Force on Responsible Use of Natural Psychedelic Substances to study existing laws, scientific data, and practices related to the use of natural resources; requiring the Task Force to make recommendations regarding any changes to State law, policies, and practices needed to create a program that enables broad, equitable, and affordable access to psychedelic substances; and requiring the Task Force to report its findings to the Governor and the General Assembly on or before July 31, 2025.

2023

HB 0927 would lower penalties for “de minimis” possession of specified levels of certain controlled substances. If passed, penalties would be reduced from criminal misdemeanors to civil fines of $100 and, in cases of people under 21, include a referral to a state-approved drug education program.

2022

On February 4, 2022, SB 709 was introduced and assigned to the Budget and Taxation and Finance committee. The bill establishes the Post–Traumatic Stress Disorder Alternative Therapies Fund as a special, nonlapsing fund, that is not subject to § 7–302 of the state finance and procurement article. The purpose of the fund is to support the department in studying the effectiveness of and improving access to alternative therapies for post–traumatic stress disorder in veterans. “Alternative therapies” includes hyperbaric oxygen therapy and psychedelics including 3,4–methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine. Governor Hogan announced on May 29, 2022, that he would allow the bill to take effect without his signature. The bill took effect on July 1, 2022.

On February 11, 2022, HB 1367 was introduced and assigned to the Appropriations committee. The bill mirrors SB 709. It hasn’t moved since its first reading at the state Senate.

HB 1054, and SB0784 were introduced which both propose to decriminalize possession of different “de minimis quantities of certain controlled dangerous substances,” including up to “40 user units of lysergic acid diethylamide (LSD),” and up to “1 gram or 5 tablets of 3,4-Methylenedioxymethamphetamine (MDMA).” If either bill is enacted, possession would be considered a civil offense carrying a maximum fine of $100 for a first offense, followed by a $150 maximum fine for a second offense. Third, and all subsequent offenses would result in a fine not to exceed $200. Under current laws, drug possession may carry prison terms and a fine of up to $5,000. Both bills were referred to committee later that month.

Maryland lawmakers sent SB0709 to the governor that would create a state fund to provide “cost-free” access to psychedelics like psilocybin, MDMA and Ketamine for military veterans suffering from post-traumatic stress disorder (PTSD) and traumatic brain injury. Maryland’s governor Larry Hogan (R) announced that he will allow SB0709 to take effect without his signature. The measure from Sen. Sarah Elfreth (D) passed unanimously through both chambers before being sent to his office.

Massachusetts has seen many psychedelics-related bills introduced over the past few years, though most have died. Currently, legislators are considering the creation of a psilocybin pilot program and decriminalization of the drug for certain groups. At the local level, personal use and possession of entheogenic plants has been made the lowest law enforcement priority in the cities of Somerville, Cambridge, Northampton, Salem and Easthampton. 

2026

H 4986 would create a psilocybin pilot program operating at five nonprofits. A related bill, H2506 (introduced in 2025), would decriminalize psilocybin for veterans, law enforcement officers, and those with qualifying conditions."

2025

H 2532, filed by Rep. Lindsay Sabadosa (D), would create, “rules and regulations necessary for the operation of a therapeutic psilocybin center” including licensure requirements and training standards for “entities that are run by medical professionals, psychiatrists, psychologists, and therapists” seeking to obtain a psilocybin facilitator license.

H 2203, filed by Cambridge state Rep. Marjorie Decker (D), is more medically-minded than HD 4017, with specific medical practitioner requirements listed for licensed facilitator status.

S 1113, filed by State Senator Cindy Friedman (D), is also medically-oriented. However, rather than the psilocybin-specifical language employed in both Rep. Sabadosa and Rep. Decker’s proposed pilot program models, SD 1624 use of the term “psychedelics” leaves room for LSD, ibogaine, MDMA, and other psychedelic substances to be administered via the pilot program it would create. H 1858 is the House version of the bill.

Cambridge Rep. Mike Connolly’s (D) H 1624 is broadly similar to Psychedelic Task Forces that have cropped up in states like Minnesota, Nevada, and Vermont. Connolly also filed HD 3020 which, while not psychedelics-specific, is a broad-ranging drug decriminalization bill.

HD 188, filed by Rep. Marc T Lombardo (R), would remove criminal penalties for personal use and possession of psilocybin while implementing certain civil fines for misuse, abuse, or unlawful commercial activity related to psychedelics.

HD 1003, filed by Rep. Patrick J. Kearney (D), proposes a limited-use licensing model for psilocybin use regulatory model that was first introduced in New Hampshire and further popularized after garnering serious legislator support in the New York State Assembly. As written, HD 1003 would establish a state-run program allowing trained and licensed individuals, such as healthcare and social work professionals, to administer psilocybin-assisted therapy to qualified patients.

S 1538, proposed by Rep. Dylan Fernandes’ (D), doesn’t explicitly mention psychedelics as currently written, but is Rep. Fernandes’ second attempt at filing a “breakthrough therapies” legislative model similar to previously proposed bills in Colorado, Virginia, New Hampshire, and Illinois, among other states, after the Representative filed a similar breakthrough therapies bill last year that gained little traction at the time.

H 1726, introduced by Representative Homar Gómez (D), —also known as the “No Harm No Foul Act”—would amend Section 34 of Chapter 94C to include a provision that allows for certain criminal complaints of simple possession of psilocybin to be dismissed so long as the offence did not cause visible harm to the health or safety of any other person. Under the proposed amendment, to qualify for dismissal, at the time of the alleged offense the individual must have been over 21 years of age, not operating a motor vehicle, and their possession must not have endangered any children.

SD 870, introduced by Cindy Friedman (D) — and also known as the “Psilocybin Possession Decriminalization and Community Support Act of 2025,” would remove criminal penalties for certain cases of psilocybin possession.

HD 4509, introduced by Jim O’Day (D), directs the state’s Department of Public Health to establish a pilot program for psychedelic-based mental health treatments, which would be geared towards building an evidence base with which to design clinical protocols and regulatory frameworks that ensure safe use. S 1400 is the Senate version of the bill.February 2025

H 2506, introduced by Representative Steve Owens (D) , would allow for qualified, lawful access to psilocybin for personal use. Under the bill, any individual clinically diagnosed with a qualifying medical condition or any U.S. veteran or law enforcement officer over the age of 21 may lawfully possess, ingest, obtain, grow, and transport up to two grams (compound weight) of psilocybin or psilocin. The proposed bill would also allow the non-remunerative transfer of psilocybin or psilocin between qualifying individuals.

2024

Question 4 is a ballot initiative to legalize botanical psychedelics and “establish a new, compassionate, culturally responsible, and effective approach to natural psychedelic substances”. Cleared for signature gathering on September 6, 2023 and qualifying for the ballot on July 01, 2024, the initiative would establish regulated access for adults aged 21 and over to natural psychedelic substances that show therapeutic potential in mental health. This includes psilocybin, psilocin, mescaline, dimethyltryptamine, and ibogaine. These substances would be purchased at an approved, state-regulated facility for use under the supervision of a licensed facilitator. After the November 05, 2024 election, this ballot did not pass.

2023

State representative Lindsay Sabadosa (D) introduced HD.1450 in the House while senator Patricia Jehlen (D) introduced SD.949 in the Senate. The text for both bills is the same, removing penalties for people over 18 years old to possess, ingest, obtain, grow, and give away, “without financial gain,” “no more than two grams of psilocybin, 8 grams psilocyn, dimethyltryptamine, ibogaine, and mescaline.” On February 16, 2023, both bills were referred to the Joint Committee on the Judiciary.

HB 3574 was introduced to establish a maximum charge of $5,000 per MDMA treatment service unit for all registered MDMA service providers. This includes those who prescribe, manufacture, distribute, dispense, or otherwise provide MDMA related services. On April 13, 2023, HB 3574 was referred to the Committee for Public Health.

Also introduced on March 30, 2023 was HB 3605, a bill calling for the Department of Public Health to establish procedures for the granting of psilocybin facilitators licenses. This bill was subsequently referred to the Committee for Public Health (also on March 30, 2023). Under the proposed licensing procedures, “[t]he minimum curriculum for a psilocybin facilitators license issued by a licensed independent training school shall be no less than 20 hours and no more than 300 hours of total training which shall include a minimum of 21 hours of in-person practicum where students facilitate and observe the facilitation of psilocybin sessions.”

Massachusetts for Mental Health Options submitted documents to the state to open a committee exploring a ballot measure allowing access and possession of psychedelics. On August 2, 2023, Massachusetts for Mental Health Options submitted the paperwork for a ballot measure titled “THE NATURAL PSYCHEDELIC SUBSTANCES ACT.” The measure would have needed to submit 75,000 signatures by the beginning of 2024 to be considered valid. There are two separate versions of the initiative, one does not permit home grow options for psilocybin and ayahuasca as opposed to alternative measure. The measure allows for possession and sharing for adults over age 21 of psilocybin, psilocin, non-peyote derived mescaline, DMT, or ibogaine. Psychedelic services would also be allowed with certification and professional licensure similar to Oregon and Colorado, however, no provisions exist for expunging prior convictions related to these compounds or services.

2021

House member Mike Connolly introduced Bill H.1494, an Act establishing a task force to study equitable access to entheogenic plants. The legislation calls to establish an interagency task force to study the public health and social justice implications of legalizing the possession, consumption, transportation, and distribution of naturally cultivated entheogenic plants and fungi. The task force is to file a report of its findings and recommendations no later than June 2022. On June 9, 2022, the bill was referred to the House Committee on Rules, accompanying study order H4844.

House Bill No. 2119 was introduced to replace the criminal penalty for unlawful possession of certain controlled substances with “a civil fine of not more than fifty dollars or participation in a needs screening to identify health and other service needs, including but not limited to services that may address any problematic substance use and mental health conditions, lack of employment, housing, or food, and any need for civil legal services.” It was referred to the Joint Committee on Mental Health, Substance Use and Recovery. On September 22, 2022, the bill was referred to the House Committee on Rules, accompanying study order H5281. 

Personal use and possession of entheogenic plants has been made the lowest law enforcement priority in the city of Ann Arbor, Detroit, Hazel Park and in Washtenaw County, of which it is the seat. The Ypsilanti City Council declared that "the investigation and arrest of individuals for entheogenic plants will be the lowest priority for the city of Ypsilanti."

2023

The Michigan State House introduced concurrent resolution No. 5. The resolution urges Congress, the DoD and the VA to invest in “non-technology treatment options for servicemembers and veterans who have psychological trauma as a result of military service.” It expands on this statement and mentions utilizing psychedelics in clinical settings as a treatment option. 

2022

Reform activists proposed an initiative that would overhaul Michigan drug laws. If passed, this initiative would decriminalize possession of Schedule 1 and 2 substances. Additionally, the initiative identified psilocybin, psilocin, ibogaine, peyote, and dimethyltryptamine as natural plants and mushrooms, which would be legal for anyone over 18 years old to cultivate, possess, use, or gift. A system of regulated sale and treatment would also be implemented. The initiative provides that entities designated by a hospital that have received a “Certificate of Need” from the Michigan Department of Health and Human Services may administer and sell “Natural Plants and Mushrooms” to patients possessing a “written recommendation” for services from a Michigan licensed physician. On June 1, 2022, activists behind the ballot initiative announced that the original target for inclusion on the ballot in 2022 has been deferred to 2024 to allow more time to gather the requisite signatures.

2021

Michigan Senators Jeff Irwin (D) and Adam Hollier (D) introduced legislation that would amend state law to decriminalize the manufacture, creation, delivery, and possession of an “entheogenic plant or fungus,” including any natural material containing DMT, ibogaine, mescaline, and psilocybin. Commercial sales would be prohibited, however the bill would permit exchange of “a reasonable fee for counseling, spiritual guidance, or a related service that is provided in conjunction with the use of an entheogenic plant or fungus under the guidance and supervision of an individual providing the service.” The legislation, SB 631, was referred to the committee on Judiciary and Public Safety.

The state-appointed Psychedelic Task Force has recommended that legislators consider decriminalizing psilocybin for personal use and possession. It has also recommended the establishment of a state-run regulated psychedelic therapy program. 

2025

The state-appointed Psychedelic Task Force recommended that state legislators seriously consider decriminalizing psilocybin for personal use and possession and establishing a state-funded regulated psychedelic therapy program for prospective patients with qualifying conditions.

HF 2699, introduced by Representative Andy Smith (D), would have eliminated criminal and civil penalties for personal use and possession of psilocybin by adults 21 years and older. 

2023

Rep. Andy Smith (D) introduced HF 1884 which would establish a “Psychedelic Medicine Task Force” to study and advise on legalizing certain psychedelic substances, such as psilocybin, LSD, and MDMA. A companion bill, SF 1954, was introduced by Sen. Kelly Morrison (D) on February 20, 2023. The task force consists of 23 members who would survey existing scientific literature and compare the efficacy of psychedelic medicines to conventional drug treatments. The first report from the task force would be due by February 1, 2024. Ultimately, the psychedelic task force was included in the omnibus health bill passing the Senate 34 to 32 and passing the House 69 to 64 as of May 23, 2023. The task force remained in the budget and was signed into law by Governor Walz. An initial report was delivered on February 1, 2024 and a final report is expected by January 1, 2025.

Considering a bill that would establish an ibogaine research program.

2026

HB 314 and SB 2561 would create an ibogaine research program. SB 2561 died in committee.

SB 2562 would have created an ibogaine pilot program for veterans with PTSD. The bill died in committee.

HB 563 and SB 2056 is a trigger law, rescheduling “any pharmaceutical composition of crystalline polymorph” in the case of federal rescheduling.

Considering bills that would create a legal framework for the therapeutic use of psilocybin; establish that veterans can use psilocybin for certain conditions; and, create an ibogaine research and treatment program.

2026

SB 1682 would make it possible for certain veterans and first responders to use psilocybin therapeutically without state legal penalties. 

HB 1643 was introduced in January. If enacted, it would create a legal framework for therapeutic use of psilocybin.

HB 1717 was introduced in January. If enacted, it would establish that veterans can use psilocybin for PTSD, major depressive disorder, substance use disorders and end-of-life care.

HB 2817, HB 2961 and SB 1581 were introduced in January. If enacted, they would create an ibogaine research program, which could also include treatment. 

2025

HB 829, filed by State Rep. Richard West (R), proposed an expansion of the 2024 veteran-focused pilot program through the Department of Mental Health. If approved, the bill would establish a state-funded psilocybin therapy program specifically for Missouri veterans over 21 who have enrolled in a psilocybin study. HB 829 was dropped from the calendar before the legislative session ended.

Two related bills were also filed in the House and Senate to expand legal protections for qualifying patients in that proposed psilocybin therapy program. HB 951, filed by Rep. Matthew Overcast (R), proposes a series of additional legal protections for qualifying patients in the program. SB 90, filed by Sen. Matthew Webber (D) proposes a similar formal expansion of legal protections for psilocybin therapy program participants. 

2023

Rep. Tony Lovasco (R) introduced HB 869, limiting its scope to psilocybin or psilocin only. HB 869 would allow psilocybin to be used by eligible patients, including those with treatment-resistant depression, PTSD, or a terminal illness. The administration of the drug would be by caregivers in a clinic, hospice, nursing home, or other approved location. Psilocybin would not be legal but the bill would create an affirmative defense against criminal prosecution. However, during a meeting of the House Veterans Committee on March 7, 2023, committee members did not consider the bill. Rep. Dan Houx (R) committed to working with Lovasco on a floor amendment to create a revised version of the bill that may pass.

HB 1154 was approved by the House Veterans Committee in a 11-0 vote. The bill was previously filed by Rep. Dan Houx (R) on February 14, 2023. The bill requires the Department of Health and Senior Services to collaborate with a higher education institution or a research organization to conduct USDA-approved trials on the efficacy of alternative medicine, including psilocybin, as treatment for PTSD, major depressive disorder, substance abuse disorders, or those who require end-of-life care. A clinical trial for psilocybin, a scientific literature review, and various reports to the Governor would be required. On May 5, 2023, the bill was “placed on the informal perfection calendar;” it’s not currently listed on the house calendar.

2022

Rep. Michael Davis (R) filed HB 2429, which was originally introduced February 18, 2021, as HB 1176. If passed, this bill would expand Missouri’s Right to Try Act to no longer prohibit people with terminal or life-threatening illnesses from using substances such as MDMA, psilocybin mushrooms, LSD, DMT, mescaline or ibogaine with a doctor’s recommendation after exhausting all other approved treatment options, if they qualify as an “investigational drug.” The bill would also reduce penalties statewide for low-level possession of those drugs. The bill was referred to the Committee for Health and Mental Health Policy on March 24, 2022. 

On January 18, 2022, with the introduction of HB 2469, Rep. Peter Merideth (D) proposed to decriminalize possession of small quantities of several scheduled substances, including MDMA, LSD, and psilocybin. Passage of this bill would create a three-tiered penalty system for possession of the outlined substances. For example, the penalty for “possession of not more than…one gram of MDMA,…forty units of LSD, [or] twelve grams of psilocybin” would be changed from a class D misdemeanor to “an infraction punishable by a fine not to exceed one hundred dollars or participation in a treatment program…or both.” Possession of more than these outlined quantities would be considered either a class A misdemeanor or a class D felony depending upon the exact amount.The bill was referred to the Committee on Crime Prevention in May 2022.

HB 2850 was introduced by Rep. Tony Lovasco (R) which proposes to legalize certain “natural medicine” including: ibogaine, psilocybin and psilocin if derived from a plant or fungus, DMT and mescaline excluding Lophophora williamsi (peyote) to treat a variety of medical conditions. The bill would also provide immunity to health care providers who recommend “natural medicines” to patients. The penalty for possession of “natural medicines” outside of the sanctioned medicinal uses would also be reduced. If enacted, possession of up to four grams of “natural medicines” would become a Class D misdemeanor carrying a maximum penalty of a $500 fine. Public hearings on the bill were completed on March 28, 2022. 

Legislators considered psychedelics-related bills in previous sessions, but none are currently under review.

2023

LC 1208 was delivered to the Executive Director for final review. This bill would have legalized psilocybin use for the treatment of certain mental health conditions, including PTSD. LC 1208 would also have established guidelines for psilocybin cultivation, manufacturing/ packaging, and administration. The bill died in committee on May 2, 2023.

2022

Montana Representative George Nicolakakos (R) initiated the process for introducing  LC 2311 to the state legislature. The bill was titled “Interim study on the use of psilocybin for treatment of mental illness” and was placed on hold December 12, 2022. The draft died in process on May 2, 2023.

No Notable Legislation

Legislation creating a working group to study the effects of MDMA and psilocybin was signed by the governor in 2023.

2025

SJR 10, introduced by seven lawmakers (all but one are Democrats) and a bipartisan suite of nearly twenty co-sponsors, urges Congress and federal agencies to boost federal funding for research into psychedelics for mental health ailments, substance use disorders, and chronic pain. It goes on to make more appeals to the federal government, including streamlining “the process for approving and conducting” psychedelic research, establishing compassionate use under the Right to Try Act, and rescheduling psilocybin (inc. psilocin), DMT, ibogaine, mescaline and MDMA. It also calls on the government to protect those operating under state-regulated psychedelics programs from federal prosecution.

AB 378, introduced by a group of eight bipartisan Representatives, would create the Alternative Therapy Pilot Program to administer psychedelic substances to patients with mental health conditions, under medical supervision and control. The psychedelics mentioned in the bill are psilocybin, psilocin, dimethyltryptamine, ibogaine and mescaline, while mental health conditions include—but are not limited to—PTSD, depression, and anxiety disorders. The drugs would be provided under the supervision of an approved practitioner, at medical facilities or approved locations, to patients who are over the age of 21, diagnosed with a mental condition, and are 'honorably discharged' veterans or were previously first responders.

2023

Lawmakers in Nevada introduced SB 242 which would decriminalize “the possession, use, consumption, cultivation, manufacturing, growing, harvesting, preparation, compounding, conversions, handling, transportation, administrations, sharing, giving away, testing or delivery of 4 ounces or less of fungi that produces psilocybin or psilocin” for individuals 18 years of age or older. Additionally, SB 242 would establish “procedures for a research facility to obtain the approval of the Department of Health and Human Services to conduct certain studies” involving MDMA and psilocybin and would allow “certain conduct by persons who are 18 years of age or older involving psilocybin and MDMA if conducted in connection with and within the scope of an approved study.” The Senate Committee on Health and Human Services made an amendment in April 2023, scaling it back from the original proposal, which would have decriminalized fungi containing small amounts of psilocybin and psilocin, and removed mention of MDMA. It passed the Senate 16-4 and the Assembly in a unanimous 40-0 vote, and was approved by the governor on June 12, 2023.

The legislature is considering a bill that would fund participation in a multistate consortium supporting clinical trials of ibogaine, and bills that would create a state medical psilocybin program. 

2026

HB 1772, introduced for the 2026 session, would appropriate $1 million to participate in a multistate consortium supporting clinical trials of ibogaine as treatment for substance use disorder and other mental health conditions.

HB 1796 and HB 1809, introduced for the 2026 session, would create a state medical psilocybin program.

2025

State Rep. Kevin Verville (R) filed HB 528, which if passed would “establish that it is not an offense for a person 21 years of age or older to obtain, purchase, transport, possess, or use psilocybin.”

2023

First introduced on January 9, 2023, HB 328-FN would legalize possession and use of LSD, mescaline, psilocybin, and peyote for persons 21 years of age and older. On March 16, 2023, the bill was deemed “inexpedient to legislate.” On March 9, 2023, HB 216-FN was rejected and was also deemed “inexpedient to legislate.” The bill would have exempted dimethyltryptamine (DMT) from the Controlled Drug Act. A different bill, HB 581-FN would have repealed the entire Controlled Drug Act and established a committee to study the necessary statutory changes to do so. The act was deemed inexpedient on February 22, 2023.

2022

HB 1349-FN was introduced to the House and referred to the Criminal Justice and Public Safety committee. The act would have decriminalized the possession or use of a certain amount of psilocybin mushrooms by a person 18 years of age or older. On March 31, 2022 the bill was ‘laid on the table.’

2020

In The State of New Hampshire v. Mack, the New Hampshire Supreme Court on December 22, 2020 vacated the trial court's order denying the defendant's motion to dismiss and remanded for further proceedings, holding that the trial court had failed to apply the compelling interest balancing test required by Part I, Article 5 of the New Hampshire Constitution. The defendant, Jeremy Mack, a member of the Oratory of Mystical Sacraments branch of the Oklevueha Native American Church, argued that his possession and use of psilocybin mushrooms was a protected religious practice. The conviction itself was not overturned by this ruling — the case was sent back to the trial court for further consideration under the correct legal standard."

On January 20, 2026, Governor Murphy signed SB 2283 into law as one of his final acts before Governor Mikie Sherrill was sworn in, establishing a two-year Psilocybin Behavioral Health Access and Therapy Pilot Program at three hospitals, allocating $6 million ($2 million per hospital) and creating an 11-member Psychedelic Therapy and Research Advisory Board. A 2021 bill also reduced the penalty for possession of one ounce or less of psilocybin to a disorderly persons offense.

2026

On January 20, 2026, Governor Murphy signed SB 2283 into law as one of his final acts before Governor Mikie Sherrill was sworn in. The law establishes a two-year Psilocybin Behavioral Health Access and Therapy Pilot Program at three hospitals (one from each of three geographic regions of the state), allocates $6 million ($2 million per institution), and creates an 11-member Psychedelic Therapy and Research Advisory Board. The program aims to determine whether New Jersey should establish a broader psilocybin care delivery system. Primary sponsors were Senate President Nick Scutari (D) and Sen. Joseph Vitale (D).

2024

Introduced in January 2024, Senate Bill 2283 was approved by the Senate Budget Committee after having been previously approved by the Senate Health and Human Services Committee. The bill has been amended to create only a regulated facilitated access model for psilocybin.

2022

Bill S2934 was introduced to the Senate and referred to Senate Health, Human Services and Senior Citizens Committee. The primary sponsor is Senator Nicholas Scutari (D). The “Psilocybin Behavioral Health Access and Services Act” would authorize production and use of psilocybin to promote health and wellness; decriminalizes, and expunges past offenses involving, psilocybin production, possession, use and distribution.

2021

Senate Bill S3256 passed. The bill amended New Jersey state law solely to provide that “Possession of one ounce or less of psilocybin is a disorderly persons offense.” Such an offense is “punishable by up to six months imprisonment, a fine of up to $1,000, or both.” Previously, possession of any amount of psilocybin was a third-degree crime punishable by 3-5 years imprisonment and a fine of up to $35,000. 

In April 2025, New Mexico Governor Michelle Lujan Grisham (D) signed SB 219, The Medical Psilocybin Act, into law. It will establish the third state-legal psilocybin access system in the U.S. aims to launch in late 2026.

2026

HB 336, introduced in February, would authorize the prescribing and dispensing of synthetic psilocybin, or drugs containing it, upon FDA approval.

2025

SB 219, introduced by Reps. Jeff Steinhorn (D), Martin Hickey (D), Elizabeth Thomson (D), Andrea Romero (D), and Craig Brandt (D), New Mexico SB 219: The Medical Psilocybin Act, proposes removing psilocybin from the Controlled Substances Act and creating a psilocybin advisory board, a treatment equity fund and a research fund to support a state-funded medical psilocybin program for patients with qualifying conditions by no later than December 31, 2027. In April, New Mexico Governor Michelle Lujan Grisham (D) signed SB 219 into law. It will establish the third state-legal psilocybin access system in the U.S.

SB 410, introduced by Craig Brandt (R), is a “crystalline polymorph psilocybin” trigger law bill. However, the Bill was tabled indefinitely on February 19, meaning it is dead.

Introduced by Representative Dayan Hochman-Vigil (D), HM 58 requests that the Department of Health study psilocybin-based treatment and its potential implementation.The bill lists many focus areas of such a study, from the standardization of training requirements and testing of psilocybin-containing substances through to regulatory and legal barriers to such treatments and frameworks for their implementation in the state.

2023

HB 393 was introduced in the New Mexico House on February 13, 2023 by Reps. Christine Trujillo, Kristina Ortez, Joy Garratt, and Willie D. Madrid. It would have created a Psilocybin Advisory Group to study and report on the feasibility of establishing a program that would use psilocybin-derived products to treat patients with certain mental health or substance use disorders in a clinical setting, establish treatment guidelines for the use of psilocybin-derived products, alongside patient selection, training, and certification, and monitor the establishment of similar programs in other states, including legal and regulatory issues. The bill has been postponed indefinitely.

2005

In a 2005 decision, State of New Mexico v. Pratt, the Court of Appeals reversed a drug trafficking conviction, holding that “the act of growing mushrooms” alone was not the “manufacture” of a controlled substance. However, intent to manufacture and distribute mushrooms is still a felony, and “manufacture” “includes any packaging or repackaging of such substance or labeling or relabeling of its container.” 

Multiple bills have been introduced to create medical psilocybin programs, establish research institutes, and decriminalize psychedelics, but no psychedelic reform has been enacted at the state level. AO 9583, which was introduced in January 2026, would create an ibogaine research program, focusing on veterans with PTSD. 

2026

AO 9583 was introduced in January. If enacted, it would create an ibogaine research program, focusing on veterans with PTSD.

2025

SB 495, introduced by Rep. Nathalia Fernandez (D) alongside four cosponsors, would create a state-supervised program permitting licensed facilitators, including health and social care professionals, to provide psilocybin-assisted therapy to eligible patients.

HB 628, filed by Rep. Linda Rosenthal (D), along with an additional eight co-sponsors, would “legalize adult possession and use of certain natural plant or fungus-based hallucinogens” including DMT, psilocybin, mescaline, ibogaine, and psilocin.

Introduced by Senator Nathalia Fernández (D) and co-sponsored by Robert Jackson (D) and Jessica Scarcella-Spanton (D), S 1801 would create a psilocybin-assisted therapy pilot program for veterans and first responders. The Assembly version of the bill is A 3845.

Introduced by Representative Pat Burke (D), A 3775 would allow for the lawful medical use of psilocybin within clinical settings and under the supervision of certified facilitators. Under the bill, facilitators would be able to access psilocybin through the Naturally Grown Psilocybin Pilot, a program also proposed in the bill.Notably, the bill also makes accessibility allowances for in-home treatments for individuals who are unable to travel. The bill would also establish a $5 million grant program to support veterans, first responders (active and retired), and low-income individuals in accessing psilocybin and/or MDMA-assisted therapy prior to their FDA approval. An advisory board would also be established to provide regular recommendations on the use of medical psilocybin in New York. Among the Board’s duties would be the development of a “long-term strategic plan for ensuring that psilocybin services will become and remain a safe, accessible and affordable therapeutic option.”

Introduced by Assemblymember Amy Paulin (D) and co-sponsored by three Democrats, A 2142 would establish a license-based framework for the regulated use of psilocybin in the state of New York. The Senate version of the bill is S 5303, introduced by Julia Salazar (D).

S 1817, introduced by Senator Nathalia Fernández (D), directs the Office of Addiction Services and Supports to “encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction.” It is co-sponsored by Jake Ashby (R). A 1522 is the Assembly version of this Bill, sponsored by Assemblymember David Weprin (D) along with Maritza Davila (D) and Keith Brown (R).

S 4664, from Senators Ashby (R) and Fernández (D), directs the Commissioner of Health to conduct a study on ibogaine for PTSD in veterans and first responders. It does not seek to appropriate any funds, but does direct the Commissioner to submit a report on the study’s findings no later than one year following its passage.

2024

On May 21, 2024, A 10375 was introduced. The bill would allow "the growth, cultivation, and regulated adult use of psilocybin for the treatment of certain health conditions; provides for the certification of support service providers and the licensure of cultivators."

2023

Assemblymember Linda B. Rosenthal (D), along with Jo Anne Simon (D) and Karines Reyes (D), introduced bill A 00114, which was referred to the health committee. A00114 would legalize “adult possession and use of certain natural plant or fungus-based hallucinogens,” specifically psilocybin, psilocin, DMT, ibogaine, and mescaline (except from peyote), and would grant “certain protections for individuals lawfully using such hallucinogens,” including losing professional licenses or employment, being denied mental health services, or being prosecuted for child abuse or neglect, based on such use. A00114 would additionally permit the “provision of supervision, guidance, peers engaging in risk mitigation, religious, spiritual, or related supportive services with or without remuneration.” The bill would also prevent NY State and local law enforcement agencies from cooperating with or assisting the federal government in enforcing the federal CSA for actions permitted under NY State law.

On January 31, 2023 Senator Nathalia Fernandez introduced S 3520. The bill “Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor.” It was referred to the Finance Committee on January 31, 2023, amended on December 20, 2023, and re-referred to the Finance Committee on January 3, 2024.

2022

Assemblymember Linda B. Rosenthal reintroduced a heavily revised version of bill (A 6065), which would have legalized psilocybin. The revised version of bill A 6065 would remove state and local prohibitions on the “possession, use, cultivation, production, creation, analysis, gifting,  exchange, or sharing by or between natural persons of twenty-one years of age or older of a natural plant or fungus-based  hallucinogen,” including DMT, ibogaine, mescaline, psilocybin, and psilocin. Additionally, this bill would authorize “supervision, guidance, peers engaging in risk mitigation, religious, spiritual, or related supportive services with or without remuneration, by natural persons of twenty-one years of  age  or older to  natural  persons of twenty-one years of age or older who are engaging in the intentional and  consenting use of natural  plant or fungus-based hallucinogens.” The bill would also direct state and local law enforcement to refrain from assisting or cooperating with the government of the United States in the enforcement of the Controlled Substances Act relating to activities authorized under the bill, except as pursuant to a valid court order.

2021

A 7928 was introduced by Assemblymember Linda B. Rosenthal and referred to the Health Committee. This bill would establish a public psychedelic research institute and a psychedelic substances therapeutic research program.

A 8569 was introduced by Assemblymember Pat Burke (D), “to enable medical professionals to receive training to administer psilo-cybin therapy ushering in an innovative treatment option for ailments such as PTSD, depression, alcohol dependency, anxiety, among others.” The bill would create a system for “Medical Use of Psilocybin,” similar to the one authorized in Oregon under Measure 109. 

Another bill, introduced during the 2021-2022 legislative session in both the Assembly (A 7109) and the Senate (S 1284), would eliminate criminal and civil penalties for possession of controlled substances, and establish a drug decriminalization task force to develop recommendations for legal reform “with the stated goal of treating substance use disorder as a disease, rather than a criminal behavior.”

Legislators considered psychedelics-related bills in previous sessions, but none are currently under review.

2025

SB 568, introduced by Senators Sophia Chitlik (D) and Bobby Haig (R), would establish a mental health and psychedelic medicine task force in the state. The task force would consider the barriers to the implementation of psychedelic medicines in the state and recommend licensing and insurance requirements for the practitioners in the event of FDA approval. It would submit a final report to the General Assembly by December 1st, 2026.

2023

HB 727 was introduced on April 18, 2023. This bill would establish the Breakthrough Therapies Research Grant Fund, awarding $5 million in total to qualifying research projects (plus an additional $400,000 for administrative costs). Grant funds under HB 727 must be used to conduct research in the State on the use of either MDMA or psilocybin. Further, qualifying MDMA research must be concentrated on treating PTSD in veterans, first responders, frontline healthcare professionals, or victims of domestic violence and/or sexual assault. Qualifying psilocybin research must be concentrated on treating anxiety or depressive disorders and must also measure pain outcomes. The bill was re-referred to the Committee on Appropriations on May 16, 2023.

No Notable Legislation

Legislators considered psychedelics-related bills in previous sessions, but none are currently under review.

2020

SB 3 would have reformed drug sentencing laws by reducing penalties from felonies to misdemeanors for certain drug possession convictions and by diverting certain offenders to treatment instead of prison. The bill was never brought up for a final floor vote.

In 2026, legislators introduced bills to create an ibogaine research framework and authorize ibogaine research at state universities.

2026

HB 3834 was introduced in January. If enacted, it would create an ibogaine research framework in a public-private partnership, in collaboration with a drug developer. 

HB 4293 was introduced in January. If enacted, it would authorize ibogaine research at state universities and research centers.

2023

February 2023, Daniel Pae (R) introduced HB 2107, to remove the threat of legal prosecution for researchers conducting studies and clinical trials using psilocybin to treat conditions like PTSD, depression, traumatic brain injury, chronic pain, and opioid use disorder, among others. After second reading, the bill was referred to the Health and Human Services Committee and then to the Appropriations Committee in late March 2023.

2022

Introduced by Rep. Phillips, HB 3174 would create a clear pathway for “academic medical centers” and physicians licensed in Oklahoma to obtain certification to conduct clinical trials using psilocybin. The bill specifies that only veterans aged 18 or older suffering from various forms of mental illness may participate in the clinical trials. 

Sponsored by Rep. Pae, HB 3414 also proposes increasing psilocybin research but provides an alternative approach which would allow anyone over 18 suffering from a list of specified conditions to participate in clinical trials. Additionally, this bill would decriminalize possession of small quantities of “psilocybin- or psilocin-containing fungi or plants,” making possession of less than 1.5 ounces, or approximately 42.5 grams, punishable by a civil penalty of $400 or less. On March 7, the republican-controlled House of Representatives voted overwhelmingly, 62-30, to pass the legislation, following which the bill moved to the Oklahoma Senate. On April 11, 2022, the Oklahoma Senate Committee on Health and Human Services voted in favor of passing HB 3414 after amendment. The committee amendment to HB 3414 removed the provisions that would have decriminalized possession of “psilocybin- or psilocin-containing mushrooms.”

In November 2020, Oregon became the first state to legalize psilocybin-assisted therapy and to decriminalize the personal possession of drugs. In April 2024, the governor signed a bill repealing much of the decriminalization measure; as of September 2024, possessing small amounts of drugs will be a misdemeanor. 

2026

HB 4110 was introduced in January. It would allow licensed physicians to prescribe ibogaine as a treatment for PTSD, major depressive disorder, anxiety disorder or substance use disorder.

HB 4040 was introduced in January. It is a large health care reform bill that includes modifications to the state's psilocybin program. If enacted, it would expand those who could provide psilocybin services and create pathways for out-of-state psilocybin facilitators to get Oregon licensure. 

2025

Co-authored by State Sen. Kim Thatcher (R) and Sen. Rick Lewis (R), with an additional co-sign from Sen. Kevin Mannix (R), SB 907 would expand the Oregon Health Authority registration requirements for psilocybin manufacturing licensees to include submission of “information regarding the ownership and location of the premises to be licensed.”

HB 2387, filed by Rep. Dacia Grayber (D),proposes enhancing legal protections for licensed psilocybin facilitators with additional health professional experience while requiring the Oregon Health Authority to keep investigations of complaints confidential. HB 2387 would also shrink the size of the Oregon Psilocybin Advisory Board down from 14-16 members to nine, require one board seat be held by a licensed service center operator and another to be held by a licensed facilitator, and implement psilocin labeling standards for all legally-manufactured psilocybin products. HB 2387 passed the House.

HB 3817, introduced by Alek Skarlatos (R) and David Smith (R), would see the Oregon Health Authority establish an access pathway for those with PTSD to access ibogaine in controlled settings. The bill envisages the pathway being established in collaboration with the VA. Importantly, the bill includes safety provisions that would require prospective users to be screened for cardiac risks and stipulates that the consumption take place in a controlled setting. 

2023

HB 2831 was introduced to the legislature. The purpose of the bill would be to repeal Measure 110 which had previously decriminalized substance possession in the state. A second bill HB 3549 would have reinstituted criminal penalties for possession of controlled substances.

SB 303 was introduced by the Senate on January 9, 2023. The bill allows for the collection of aggregate data from licensed psilocybin service centers, and forward this information to the Oregon Health Authority and Oregon Health and Science University. All aggregated data would be made publicly available. Clients could also request their information be kept confidential. The bill was passed by both chambers and signed by the governor.

2022

SB 1580 would create a task force to investigate and make recommendations about how to address issues related to equity and access to psilocybin services under Oregon’s burgeoning psilocybin services program. The task force is charged with making recommendations about a variety of equity and access topics including how to address barriers keeping people of color and people who are low income from participating in Oregon’s burgeoning psilocybin services program as business owners, facilitators, or clients. This bill was placed in committee upon adjournment in March 2022 with no further movement. 

2021

Measure 110, the Drug Addiction Treatment and Recovery Act, went into effect on February 1, 2021. It reclassified personal possession of small amounts of drugs as a civil violation with a $100 maximum fine, which can be avoided if the person agrees to seek treatment. For possession of slightly larger amounts of some drugs, the penalty was reduced from a felony to misdemeanor possession. Treatment services are to be funded by marijuana tax revenue. Criminal penalties still apply for commercial drug activities and possession of larger amounts. Measure 110 was largely repealed in 2024.

2020 

Measure 109, the Oregon Psilocybin Services Act, directs the Oregon Health Authority (OHA) to license and regulate the manufacturing, transportation, delivery, sale and purchase of psilocybin products and the provision of psilocybin services. A two-year development period is allowed for from January 1, 2021 to December 31, 2022, during which the OHA worked with the Oregon Psilocybin Advisory Board to establish rules and regulations implementing Measure 109 and the use of psilocybin products and services. Applications related to the manufacture, sale and purchase of psilocybin products and the provision of psilocybin services were accepted starting on January 2, 2023.

A trigger law was introduced in January 2026.

2026

SB 1149 was introduced in January. A trigger law, it would reschedule a pharmaceutical composition of synthetic psilocybin in the state if it receives FDA approval and DEA rescheduling.

2022

HB 2421 (previously HB 1959) was introduced by Rep. Tracy Pennycuick (R) and referred to the Health committee. The Psilocybin Data Act provides for research and clinical studies of psilocybin and psilocybin-assisted therapy. The act provides a framework for research to discover innovative methods to optimize the public health benefits of psilocybin. The bill was not reintroduced in the 2023-24 session and is presumed dead. 

2021

The Public Health Benefits of Psilocybin Act (HB 1959), was introduced by Rep. Tracy Pennycuick (R) and 20 other co-sponsors, and referred to the Health Committee. A co-sponsorship memorandum with Rep. Jennifer O’Mara (D) explains the legislation would “authoriz[e] clinical study of the efficacy and cost/benefit optimization of psilocybin-assisted therapy in the treatment of PTSD, traumatic brain injury and various mental health conditions, with prioritization of funding and treatment for veterans, first responders, and their families.” For purposes of the study, the legislation would also “authorize limited cultivation of psilocybin under the authority of state law.” The law passed in Texas on June 18, 2021 (HB 1802) was noted as a model. 

Legislation has been introduced to legalize psilocybin for personal use and cultivation and establish an FDA-dependent State-regulated therapeutic access program.

2026

H7756 would allow individuals to cultivate psilocybin within their homes for personal use. In the case of FDA approval of psilocybin, it would mandate that the state Department of Health establish rules and regulations on cultivation, distribution, and medical prescription of psilocybin. It was introduced in February.

2025

State Rep. Brandon Potter (D), along with nine Democrat co-sponsors, filed HB 5186. The Bill would both legalize psilocybin for personal use and cultivation and establish an FDA-dependent State-regulated therapeutic access program. The bill was referred to the House Judiciary Committee for further review, where it was "held for future study."

2023

HB 5923 (the Uniform Controlled Substances Act) and S 0806 were introduced in the House and the Senate, respectively. If passed, the bill would amend the current law on controlled substances to permit a person to be in possession of less than one ounce of psilocybin. It would also permit psilocybin to be securely cultivated within a person’s residence for personal use." The bill further stipulates that: 1) Should the FDA reschedule psilocybin, “the Rhode Island department of health will establish rules and regulations pertaining to cultivation, distribution and medical prescription,” and 2) Should the FDA reschedule psilocybin, “the Rhode Island department of health shall establish rules and regulations pertaining to cultivation, distribution and medical prescription.” HB 5923 passed the House and was referred to the Senate Judiciary Committee.

2022

HB 7715 was introduced proposing to build upon Rhode Island’s existing marijuana decriminalization policy by decriminalizing possession of psilocybin and buprenorphine. If passed, possession of up to one ounce of “buprenorphine, psilocybin and the substance classified as marijuana” would be exempted from criminal penalties associated with possession of scheduled substances. While “the substance classified as marijuana” is currently exempt from criminal penalties, possession of up to one ounce is considered a civil offense carrying a $150 fine and requiring forfeiture of the substance. However, as currently proposed, possession of up to one ounce of “psilocybin” or “buprenorphine” would not carry any civil penalty under this bill. 

On March 4, 2022, another bill proposing to decriminalize possession of certain drugs, HB 7896, was introduced. If enacted, this bill would decriminalize possession of up to one ounce of any “controlled substance classified in schedules I, II, III, IV, and V, except the substance classified as fentanyl.” Possession of up to one ounce of these controlled substances would result in a $100 fine for a first offense, and up to $300 for subsequent offenses. The committee recommended this bill also be held for further study on April 13, 2022.

2021

SB 604 was introduced. The bill would decriminalize minor drug possession, instead making it a civil violation punishable by a $100 fine, and the possibility of drug counseling and community service. Currently, possession is punishable by up to three years imprisonment and a fine between $500 and $5,000. On March 25, 2021, the Judiciary Committee recommended the bill be held for further study.

No Notable Legislation

In 2026, a trigger law was introduced. A trigger law automatically changes state drug scheduling if and when the federal government acts first — in this case, if the FDA approves and DEA reschedules a form of synthetic psilocybin.: a trigger law to reschedule a form of psilocybin.

2026

HB 1099 was introduced in January. A trigger law, it would reschedule “pharmaceutical composition of crystalline polymorph psilocybin” in the state upon FDA approval and DEA rescheduling.

In 2026, legislation was introduced to support trials researching ibogaine.

2026

HB 2075 and SB 2149 were introduced in January and early February, respectively. They would create an ibogaine research framework.

In 2025, legislation was passed to establish a grant program to support FDA-approval-aligned drug development of ibogaine treatment for opioid use disorder, co-occurring substance use disorder, and "any other neurological or mental health conditions for which ibogaine demonstrates efficacy."

2025

Introduced by Senator César Blanco (D), SB 3005 would instruct the Department of State Health Services to conduct a study in consultation with the Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School at UT Austin. That study would investigate the use of psychedelic therapies for PTSD, depression, and "other co-occuring conditions." The bill would require the Department to submit a report by December 1, 2026.The House version of the bill, HB 4014, is sponsored by Representative John Bucy (D).

Introduced by Senator Tom Parker (R), SB 2308 would establish a grant program to support FDA-approval-aligned drug development of ibogaine treatment for opioid use disorder, co-occuring substance use disorder, and "any other neurological or mental health conditions for which ibogaine demonstrates efficacy."The House version of this bill, HB 3717, is sponsored by Representative Cody Harris (R). Governor Greg Abbott signed SB 2308 into law on June 11, 2025, effective immediately. The law establishes a grant program providing up to $50 million in state matching funds for a public-private consortium — consisting of a drug developer, a state institution of higher education, and a hospital — to conduct FDA drug development trials with ibogaine.

2023

Representative Richard Peña Raymond (D) filed HB 4288. This bill would conduct studies on alternative therapies for PTSD, particularly MDMA, psilocybin and ketamine in veteran populations. It was read before the House and referred to the Public Health Committee on March 21, 2023.

Representative Josey Garcia (D) introduced HB 4423. The bill would establish a psilocybin research council. The council would advise the use of appropriating funds for research on psilocybin in the context of psychiatric and neurological disorders. 

Representative Julie Johnson (D) introduced HB 4561, titled “Relating to the establishment of the Alternative Mental Health Therapy Research Consortium…” The consortium would establish a program to allow ketamine clinics in the state and “evaluate the efficacy of using alternative therapies, including the use of ibogaine and 5-MeO-DMT, to treat veterans who suffer from post-traumatic stress disorder, depression, and mild traumatic brain injury.” A report would be due by December 1, 2024. 

2021

HB 1802 became law. It will be in effect from September 1, 2021 until it expires September 1, 2025. The bill calls for a study led by the Department of State Health Services to evaluate the therapeutic efficacy of alternative therapies including MDMA, psilocybin, and ketamine for the treatment of PTSD. The department will evaluate and compare the efficacy of these novel treatments with current treatments, and prepare and submit a report by December 1, 2024.

Senate Bill 266 became law in March 2024, creating a pilot program for Intermountain Health and University of Utah Health to offer MDMA and psilocybin treatments. In 2026, legislators introduced a bill to create a clinical trial for veterans with PTSD and a trigger law that would reschedule crystalline polymorph psilocybin.

2026

HB 0390 was introduced in January. If enacted, it would create a clinical trial, researching psychedelic-assisted therapy as a treatment for veterans with PTSD. 

SB 0114 was introduced in January. A trigger law, it would reschedule crystalline polymorph psilocybin in the state upon FDA approval and DEA rescheduling.

2025

Introduced by Senator Kirk Cullimore (R), SB 248 is a rescheduling trigger law bill that would automatically reschedule “the pharmaceutical composition of crystalline polymorph psilocybin” should it be federally rescheduled. The bill also allows health care providers such as palliative care providers, licensed psychiatrists, and qualified health systems to develop and lawfully provide behavioural health treatments that incorporate the use of psilocybin and MDMA to patients under their supervision. 

2024

SB 266, sponsored by Senator Kirk Cullimore (R) and Representative James Dunnigan (R), was introduced in the Senate in February 2024 and became law a month later. The bill creates a pilot program for two healthcare systems, Intermountain Health and University of Utah Health, to offer MDMA and psilocybin treatments.

2023

SB 200 was introduced to the Senate. The bill would legalize psilocybin therapy for those over the age of 21 in the context of certain psychiatric diagnoses. It would also provide for the state regulation of psilocybin production and therapy. It was filed in the Senate on March 3, 2023 as “bills not passed.”

2022

HB 167 was introduced by Utah State Rep. Brady Brammer (R). This bill proposed the creation of a task force charged with “provid[ing] evidence-based recommendations on any psychotherapy drug that the task force determines may enhance psychotherapy when treating a mental illness.” Governor Spencer Cox signed HB 167 into law, creating the Mental Illness Psychotherapy Drug Task Force.

A Psychedelic Therapy Advisory Working Group was established in 2024. In 2026, legislators introduced a bill to create a Psychedelic Therapy Advisory Board and appropriate $300,000 for ibogaine studies.

2026

H 0859 would create a Psychedelic Therapy Advisory Board and appropriate $300,000 for ibogaine studies. It was introduced in February.

2025

Introduced by Representative Troy Headrick (D), H 189 would create a Drug Use Health and Safety Advisory Board tasked with establishing benchmark personal use supplies for regulated drugs, including psychedelics. Individuals possessing amounts less than the established benchmarks would not face criminal or civil sanctions, but would be subject to health needs screenings instead.

Introduced by Senator Tanya Vyhovsky (D), SB 120 would create the Drug Use Health and Safety Advisory Board to determine benchmark levels of supply for each regulated drug, including LSD and MDMA, under discussion (by January 1, 2026), with the goal of reducing or preventing criminalization.According to the Bill, people caught in possession of drugs
under the benchmark would be offered comprehensive health needs screening.

Sponsored by Senator Martine Gulick (D), SB 106 would renew the state's Psychedelic Therapy Advisory Working Group until January 1, 2026.

Introduced by Representative Brian Cina (D), H 452 would decriminalize the possession, cultivation and noncommercial personal use of psilocybin-containing mushrooms by adults. It would also establish the "Psilocybin Therapeutic Consultation Program," which would be a state-licensed program.

2024

Approved and signed by the Governor of Vermont on May 29th, 2024, S 114 concerns the “establishment of the Psychedelic Therapy Advisory Working Group”. This group would review existing research on the cost-benefit profile of the use of psychedelics to improve mental health, and to make findings and recommendations regarding the advisability of the establishment of a State program to permit health care providers to administer psychedelics in a therapeutic setting and the impact on public health of allowing individuals to legally access psychedelics under State law. The Working Group is required to submit a written report, on or before November 15, 2024, to the House and Senate Committees on Judiciary, the House Committee on Health Care, the House Committee on Human Services, and the Senate Committee on Health and Welfare with its findings and any recommendations for legislative action. The Working Group will have the assistance of the Vermont Department of Mental Health, in collaboration with the Vermont Psychological Association, for purposes of scheduling and staffing meetings and developing and submitting the report.

2023

H 371 was introduced to the legislature and heard before the House Judiciary Committee. This bill would decriminalize psilocybin possession and distribution in addition to establishing a work group to investigate its therapeutic potential. This also joined bills S 119 and H 423 which would launch safe supply services run by the Vermont Department of Health.

H 439, “An act relating to decriminalizing certain chemical compounds found in plants and fungi that are commonly used for medicinal, spiritual, religious, or entheogenic purposes,” sponsored by Representatives Cina, Troiano, Buss, Farlice-Rubio, Headrick, Hooper, LaMont, McCann, Priestley, Sammis, Small and Templeman. VHB 439 would remove the following from the definition of “Hallucinogenic Drugs”: mescaline, peyote and psilocybin from definition of “Hallucinogenic Drugs”; and, would remove the following from the definition of “Regulated Drug”: peyote, ayahuasca, mescaline, psilocybin, psilocin, ibogaine; N,N-dimethyltryptamine; or any plants or fungi containing mescaline, psilocybin, psilocin, ibogaine; N,N-dimethyltryptamine. These definitional changes would (a) remove the foregoing substances from the criminal prohibition contained at Section 4205 and (b) the criminal penalties contained at Section 4235, of Title 18, Chapter 84: Possession And Control Of Regulated Drugs.

S 114 was introduced on March 1, 2023. “This bill proposes to make findings regarding the therapeutic benefits of psilocybin, to remove criminal penalties for possession of psilocybin; and to establish the Psychedelic Therapy Advisory Working Group to examine the use of psychedelics to improve physical and mental health and to make recommendations regarding the establishment of a State program similar to Connecticut, Colorado, or Oregon to permit health care providers to administer psychedelics in a therapeutic setting.” The bill was signed into law by the governor in May 2024.

2022

H 644 was introduced and referred to the Judiciary Committee. This bill is an act relating to decriminalization of a personal use supply of a regulated drug. The bill “proposes to change the penalties for possession of a personal use supply of drugs from a misdemeanor or low-level felony to a civil offense subject to a $50.00 penalty. A person cited for such an offense may avoid paying the penalty by agreeing to participate in a screening for substance use disorder treatment and related services. The bill would also establish the Drug Use Standards Advisory Board for the purpose of determining the benchmark personal use dosage and the benchmark personal use supply for regulated drugs with a goal of preventing and reducing the criminalization of personal drug use.” The bill didn’t make it past introduction in the House.

2021

H 309 was introduced and referred to the Judiciary Committee. The bill would decriminalize compounds found in plants and fungi that are used for medicinal, spiritual, religious, or entheogenic purposes, including psilocybin, psilocin, mescaline, peyote, DMT, and ibogaine.

H 422 was introduced and referred to the Human Services Committee. The bill would decriminalize possession of “personal use supply” of certain drugs, in an amount to be determined by a Drug Use Standards Advisory Board established within the Department of Health—based on what is “commonly possessed for consumption by an individual for any therapeutic, medicinal, or recreational purpose,” and with the goal of preventing and reducing the criminalization of personal drug use. Possession of drugs under such amounts would be a civil violation subject to a fine of up to $50 or a referral to a substance use screening and health service. Currently, personal possession carries criminal penalties of up to three years in prison and up to $75,000 in fines.

Legislators considered psychedelics-related bills in previous sessions, but none are currently under review.

2026

HB 1347/SB 379 were introduced in January. A trigger law, it would reschedule psilocybin administered by a healthcare professional in the state upon FDA approval and DEA rescheduling. 

2025

SB 1101, filed by Sen. Ghazala Hashmi (D) and co-sponsored by Sen. Jennifer Boysko (D), doesn’t mention any specific psychedelics in the proposed bill’s current language. However, similarly to Massachusetts’ recently filed SD 323, the bill would create a “Breakthrough Therapies for Veteran Suicide Prevention Fund to provide funding to support clinical research and implementation of FDA Breakthrough Therapies.” On February 17, 2025, the bill was unanimously passed by indefinitely by the Committee on Rules, which means the bill is dead.

SB 1135, a trigger law sponsored by Sen. Jennifer Boysko (D),would “direct the Virginia Board of Pharmacy to promulgate regulations that would allow for the prescribing, possessing, dispensing and use of Crystalline Polymorph Psilocybin” upon its FDA approval and federal rescheduling.. SB 1135 passed both the Virginia House and Senate but was vetoed by Governor Youngkin on March 24, 2025. The Senate sustained the veto on April 2.

2023

On January 11, Rep. Adams (D) introduced HB 1513, which would allow possession of psilocybin pursuant to a valid prescription by a health care practitioner in the course of professional practice for treatment of refractory depression or PTSD or to ameliorate end-of-life anxiety. The bill would prohibit prosecution of health care practitioners or pharmacists for dispensing or distributing psilocybin for such purposes. The bill would also make possession of psilocybin without a valid prescription a Class 2 misdemeanor punishable by no longer than 30 days in jail and no more than a $500 fine. It was referred to the Committee for Courts of Justice. On January 18, 2023 the House subcommittee recommended the bill be laid on the table, and in February 2023, the bill was left in the Courts of Justice. 

Also on January 11, SB 932 was introduced by Sens. Hashmi and Boysko, and would establish a Virginia Psilocybin Advisory Board to “develop a long-term strategic plan for establishing therapeutic access to psilocybin services and monitor and study federal laws, regulations, and policies regarding psilocybin.” The Advisory Board would be constituted of 12 nonlegislative citizen members to be appointed by the Governor and would report annually to the Governor and General Assembly. The bill would also reclassify psilocybin under the state Drug Control Act from a Schedule I to a Schedule III controlled substance. It was referred to the Committee on Education and Health. On February 7, 2023, SB 932 was read a third time and passed in the Senate 25 to 15.

2022

On January 12, SB 262 was introduced by State Senators Ghazala Hashmi (D) and Jennifer Boysko (D) to decriminalize possession of psilocybin and psilocin and referred to the committee on the Judiciary. The bill provides that any person 21 years of age or older who knowingly or intentionally possesses psilocybin or psilocin shall be punished by a civil penalty of no more than $100 and such civil penalties shall be deposited into the Drug Offender Assessment and Treatment Fund. Under current law, a person who knowingly or intentionally possesses psilocybin or psilocin is guilty of a Class 5 felony. On January 31, 2022, the Senate Judiciary Committee voted to change the status of the bill to  “passed by indefinitely” .  The committee may reconsider the legislation at a later meeting but if the committee takes no further action, the bill is dead.

Additionally, on January 12, State Representative Dawn Adams (D), a nurse practitioner, introduced HB 898 which called for the decriminalization of peyote and ibogaine possession in addition to psilocybin and psilocin. If passed, this bill will reduce the penalty for possession of psilocybin, psilocin, ibogaine and peyote for individuals aged 21 and over from a Class 5 felony to a civil offense carrying a maximum $100 fine. Similar to SB 262, HB 898 also provided that “any civil penalties collected” for possession of the named scheduled substances “shall be deposited into the Drug Offender Assessment and Treatment Fund.” This fund would be used by the state assembly to support various treatment programs for individuals struggling with substance abuse. On January 24, 2022, HB 898 was shelved for the legislative session.

Washington has enacted a psilocybin therapy pilot program through the University of Washington for veterans and first responders (SB 5263, signed May 9, 2023). Multiple jurisdictions have deprioritized enforcement of entheogen laws, including Seattle (2021), Port Townsend (2021), Jefferson County (2023), Olympia (2024), and Tacoma (January 28, 2025).

2026

SB 5921 would create a state medical psilocybin program, starting on July 1, 2028. It was introduced in January.

2025

Filed by Washington State Senator Jesse Solomon (D) in tandem with eight additional co-sponsors, SB 5201 would create a regulated structure for psilocybin-assisted therapeutic services by state-licensed facilitators.

Filed by State Rep. Roger Goodman (D) with co-sponsorship from Rep. Tarra Simmons (D) and Rep. Natasha Hill (D), HB 1281 is a veterans and first responders-focused pilot program bill that would “offer psilocybin therapy services through pathways approved by the federal food and drug administration… to first responders and veterans who are 21 years of age or older and experiencing posttraumatic stress disorder, mood disorders, or substance use disorders.” A range of medical professionals would be eligible to provide the services, including “advanced social workers, independent clinical social workers, mental health counselors, physicians, psychiatric nurse practitioners, and registered nurses.” 

HB 1433, filed by Rep. Nicole Macri (D) with bipartisan co-sponsors, would create a regulated framework for psilocybin-assisted therapeutic services, with explicit provisions addressing affordability, equity, and access — including acknowledgment that cost of services is a barrier to participation in psychedelic programs.

SB 5204, filed by Sen. Jesse Salomon (D) with co-sponsorship from Sen. Yasmin Trudeau (D) and Sen. T’wina Nobles (D), would provide funding for the University of Washington to “conduct a randomized cohort study over a three-year period” in partnership with a licensed ibogaine clinic in Mexico that would also include “structured therapeutic support.”

2023

SB 5263 was introduced before the Washington Senate. On March 7, it passed in the Senate and was referred to the House. The law would direct the Department of Health (DoH) to administer a regulatory system for supported adult-use of psilocybin. DoH would be tasked with creating standards for manufacturing, testing, packaging, and labeling psilocybin products with the assistance of a Psilocybin Advisory Board and other state agencies. Persons over the age of 21 would be able to purchase psilocybin products in a psilocybin service center and undergo a preparation session, administration session, and integration session under the supervision of a trained and qualified facilitator. A substitute to SB 5263 was signed by the Governor on May 9, 2023. The pilot project remains limited to veterans and first-responders being treated with psilocybin. Governor Inslee partially vetoed the bill on May 9, 2023, eliminating provisions that would have created a Psilocybin Advisory Board and an Interagency Psilocybin Work Group. The Psilocybin Task Force and the University of Washington clinical pilot program were retained.

2022

Washington lawmakers introduced SB 5660, a bill that would legalize the supported adult use of psilocybin by people 21 years of age and older.  Similar to Oregon’s Psilocybin Services Act, passed by voter ballot initiative under Measure 109 in 2020, the Psilocybin Services Wellness and Opportunity Act would enable the Washington Department of Health to issue licenses to psilocybin manufacturing facilities, testing labs, service centers, and facilitators. It would also create the Washington Psilocybin Advisory Board to advise the Department on creating rules for the Act’s implementation. Despite bipartisan interest in SB 5660, the bill failed to make it out of committee, though lawmakers are said to be likely to attempt similar reform measures soon.
The Washington state legislature sent a state budget bill, SB 5693, to the governor’s desk that included a proposal to direct $200,000 in funding to support a new workgroup to study the possibility of legalizing psilocybin services in the state, including the idea of using current marijuana regulatory systems to track psychedelic mushrooms. The proposed budget became effective on March 31, 2022. The work group will receive $50,000 of funding for FY 2022 and the remainder for FY 2023. A final report on the group’s findings must be submitted by December 2023.

2021

In the case of State v. Blake the Washington Supreme Court briefly decriminalized drug possession by judicial decree, declaring felony criminal penalties for knowing or unknowing possession of controlled substances to be unconstitutional. In response, Washington’s legislature overhauled the state’s drug possession statutes.  Effective July 25, 2021, SB 5476 encourages law enforcement officers and prosecutors to divert first- and second-time possession offenders to assessment, drug treatment, and services.  The law reduces the penalty for possession of a controlled substance to a misdemeanor rather than a felony.  The penalty provisions expire after two years, giving lawmakers time to review the effects of the new policy.

In 2026, legislators introduced bills to create a grant program funding ibogaine research, a program for medical treatment of PTSD with psilocybin and trigger laws to reschedule crystalline polymorph psilocybin. An ibogaine research bill (HB 4626) has already passed the House.

2026

HB 4640, HB 4721 and SB 906 are a trigger law, which would reschedule crystalline polymorph psilocybin. 

HB 4626 would create a grant program to fund FDA drug development trials with ibogaine for the treatment of opioid use disorder and other conditions. The bill passed the House on January 29, 2026, in a 96–0 vote, and is pending before the Senate Health and Human Resources Committee.

HB 5588 would establish a program for the medical use of psilocybin as treatment for PTSD. 

2025

Introduced by Delegate Evan Worrell (R), HB 3344 would establish a grant program to fund clinical trials of ibogaine with the goal of FDA approval. The bill passed the House but was put on hold in the Senate.

HB 3343, introduced by Worrell, is a crystalline polymorph psilocybin rescheduling trigger law bill. The bill passed the House.

2023

HB 2951 was introduced to the House by Delegate Kayla Young. The bill would remove the Schedule I status of several drugs from the Code of West Virginia including THC and psilocybin.

2021

HB 3113 proposed removing certain substances from schedule I of the Uniform Controlled Substances Act, including psilocybin. The bill made it as far as Health and Human Resources before the Legislature adjourned without assigning a future date for a meeting or hearing.

No Notable Legislation

No Notable Legislation